Coherus Makes U-Turn On Eylea Biosimilar With Klinge BioPharma Deal
Cash-And-Stock Deal Brings In Exclusive Comm. Rights From Formycon Partner
Buoyed by the recent launch and leverage of its biosimilar ranibizumab biosimilar, Coherus BioSciences has brokered a deal with Klinge BioPharma/Formycon for the commercialization rights to the firms’ Eylea (aflibercept) biosimilar candidate
